THOR LX2.3 with LED Lollipop for Mouth Sores

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mouth Sores+3 MoreTHOR LX2.3 with LED Lollipop - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is evaluating the use of a device called the THOR LX2.3 with LED Lollipop for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). This device uses light to help prevent mucositis, a common side effect of alloHCT.

Eligible Conditions
  • Mouth Sores
  • Intraoral Photobiomodulation Therapy
  • Mouth Ulcer
  • Allogeneic Bone Marrow Transplant

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 20 Days

20 Days
Duration of severe Oral Mucositis

Trial Safety

Trial Design

1 Treatment Group

INTRAORAL PBMT IN PATIENTS UNDERGOING alloHCT
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: THOR LX2.3 with LED Lollipop · No Placebo Group · N/A

INTRAORAL PBMT IN PATIENTS UNDERGOING alloHCT
Device
Experimental Group · 1 Intervention: THOR LX2.3 with LED Lollipop · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 20 days

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,016 Previous Clinical Trials
393,778 Total Patients Enrolled
THOR Photomedicine LtdUNKNOWN
Kentaro Ikeda, DDS, MPHPrincipal InvestigatorBrigham and Women's Hospital
Nathaniel S. Treister, DMD, DMScPrincipal InvestigatorBrigham and Women's Hospital
1 Previous Clinical Trials
40 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to understand the nature and purpose of the study and are willing to sign a written informed consent document.